Cargando…

Sustainable vaccine development: a vaccine manufacturer's perspective

Vaccination remains the most cost-effective public health intervention after clean water, and the benefits impressively outweigh the costs. The efforts needed to fulfill the steadily growing demands for next-generation and novel vaccines designed for emerging pathogens and new indications are only r...

Descripción completa

Detalles Bibliográficos
Autores principales: Rappuoli, Rino, Hanon, Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: GlaxoSmithKine Biologicals SA. Published by Elsevier Ltd. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126290/
https://www.ncbi.nlm.nih.gov/pubmed/29751212
http://dx.doi.org/10.1016/j.coi.2018.04.019
_version_ 1783516116256030720
author Rappuoli, Rino
Hanon, Emmanuel
author_facet Rappuoli, Rino
Hanon, Emmanuel
author_sort Rappuoli, Rino
collection PubMed
description Vaccination remains the most cost-effective public health intervention after clean water, and the benefits impressively outweigh the costs. The efforts needed to fulfill the steadily growing demands for next-generation and novel vaccines designed for emerging pathogens and new indications are only realizable in a sustainable business model. Vaccine development can be fast-tracked through strengthening international collaborations, and the continuous innovation of technologies to accelerate their design, development, and manufacturing. However, these processes should be supported by a balanced project portfolio, and by managing sustainable vaccine procurement strategies for different types of markets. Collectively this will allow a gradual shift to a more streamlined and profitable vaccine production, which can significantly contribute to the worldwide effort to shape global health.
format Online
Article
Text
id pubmed-7126290
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher GlaxoSmithKine Biologicals SA. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71262902020-04-08 Sustainable vaccine development: a vaccine manufacturer's perspective Rappuoli, Rino Hanon, Emmanuel Curr Opin Immunol Article Vaccination remains the most cost-effective public health intervention after clean water, and the benefits impressively outweigh the costs. The efforts needed to fulfill the steadily growing demands for next-generation and novel vaccines designed for emerging pathogens and new indications are only realizable in a sustainable business model. Vaccine development can be fast-tracked through strengthening international collaborations, and the continuous innovation of technologies to accelerate their design, development, and manufacturing. However, these processes should be supported by a balanced project portfolio, and by managing sustainable vaccine procurement strategies for different types of markets. Collectively this will allow a gradual shift to a more streamlined and profitable vaccine production, which can significantly contribute to the worldwide effort to shape global health. GlaxoSmithKine Biologicals SA. Published by Elsevier Ltd. 2018-08 2018-05-08 /pmc/articles/PMC7126290/ /pubmed/29751212 http://dx.doi.org/10.1016/j.coi.2018.04.019 Text en © 2018 GlaxoSmithKine Biologicals SA Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Rappuoli, Rino
Hanon, Emmanuel
Sustainable vaccine development: a vaccine manufacturer's perspective
title Sustainable vaccine development: a vaccine manufacturer's perspective
title_full Sustainable vaccine development: a vaccine manufacturer's perspective
title_fullStr Sustainable vaccine development: a vaccine manufacturer's perspective
title_full_unstemmed Sustainable vaccine development: a vaccine manufacturer's perspective
title_short Sustainable vaccine development: a vaccine manufacturer's perspective
title_sort sustainable vaccine development: a vaccine manufacturer's perspective
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126290/
https://www.ncbi.nlm.nih.gov/pubmed/29751212
http://dx.doi.org/10.1016/j.coi.2018.04.019
work_keys_str_mv AT rappuolirino sustainablevaccinedevelopmentavaccinemanufacturersperspective
AT hanonemmanuel sustainablevaccinedevelopmentavaccinemanufacturersperspective